Johnson & Johnson

144.68+0.6800+0.47%Vol 13.75M1Y Perf 4.92%
Nov 30th, 2020 16:00 DELAYED
BID143.50 ASK145.00
Open144.23 Previous Close144.00
Pre-Market144.10 After-Market-
 0.10 0.07%  - -
Target Price
168.25 
Analyst Rating
Moderate Buy 1.56
Potential %
16.78 
Finscreener Ranking
★★     47.52
Insiders Trans % 3/6/12 mo.
-100/-100/-60 
Value Ranking
★★+     50.29
Insiders Value % 3/6/12 mo.
-100/-100/-95 
Growth Ranking
★★★★     62.22
Insiders Shares Cnt. % 3/6/12 mo.
-100/-100/-95 
Income Ranking
★★★     46.02
Market Cap380.88B 
Earnings Rating
Neutral
Price Range Ratio 52W %
74.25 
Earnings Date
13th Oct 2020

Today's Price Range

143.06144.86

52W Range

109.16157.00

5 Year PE Ratio Range

14.30310.40

Summary:

Buy

Technical Indicators: Neutral
Moving Averages: Strong Buy
Performance
1 Week
-1.61%
1 Month
4.08%
3 Months
-6.27%
6 Months
-2.02%
1 Year
4.92%
3 Years
2.84%
5 Years
41.69%
10 Years
170.85%

TickerPriceChg.Chg.%
JNJ144.680.68000.47
AAPL119.052.46002.11
GOOG1 760.74-32.4500-1.81
MSFT214.07-1.1600-0.54
XOM38.12-2.0700-5.15
WFC27.41-1.0500-3.69
FB276.97-0.8400-0.30
GE10.18-0.2200-2.12
JPM117.88-3.3400-2.76
Financial StrengthValueIndustryS&P 500US Markets
1.20
1.50
0.34
0.59
96.80
Leverage Ratio 2.60
ProfitabilityValueIndustryS&P 500US Markets
65.70
23.80
32.60
24.20
21.13
RevenueValueIndustryS&P 500US Markets
80.86B
30.71
2.22
3.42
DividendsValueIndustryS&P 500US Markets
2.76
4.04
5.36
5.77
Payout ratio67.00
Earnings HistoryEstimateReportedSurprise %
Q03 20201.992.2010.55
Q02 20201.501.6711.33
Q01 20202.032.3013.30
Q04 20191.861.881.08
Q03 20192.002.126.00
Q02 20192.422.586.61
Q01 20192.032.103.45
Q04 20181.951.971.03
Earnings Per EndEstimateRevision %Trend
12/2020 QR1.82-4.21Negative
12/2020 FY7.991.78Positive
3/2021 QR2.22-1.77Negative
12/2021 FY9.000.67Positive
Next Report Date-
Estimated EPS Next Report1.99
Estimates Count7
EPS Growth Next 5 Years %5.80
Volume Overview
Volume13.75M
Shares Outstanding2.63B
Trades Count104.46K
Dollar Volume3.50B
Avg. Volume8.08M
Avg. Weekly Volume7.03M
Avg. Monthly Volume7.21M
Avg. Quarterly Volume6.67M

Johnson & Johnson (NYSE: JNJ) stock closed at 144 per share at the end of the most recent trading day (a 0.22% change compared to the prior day closing price) with a volume of 3.06M shares and market capitalization of 380.88B. Is a component of S&P 500, Dow Jones 30, Russell 1000 indices and it is traded on NYSE exchange. The company belongs in the Drug Manufacturers industry, Healthcare sector and employs 135100 people. Johnson & Johnson CEO is Alex Gorsky.

The one-year performance of Johnson & Johnson stock is 4.92%, while year-to-date (YTD) performance is -1.28%. JNJ stock has a five-year performance of 41.69%. Its 52-week range is between 109.16 and 157, which gives JNJ stock a 52-week price range ratio of 74.25%

Johnson & Johnson currently has a PE ratio of 23.00, a price-to-book (PB) ratio of 5.98, a price-to-sale (PS) ratio of 4.77, a price to cashflow ratio of 18.10, a PEG ratio of 2.32, a ROA of 10.02%, a ROC of 17.93% and a ROE of 26.64%. The company’s profit margin is 21.13%, its EBITDA margin is 32.60%, and its revenue ttm is $80.86 Billion , which makes it $30.71 revenue per share.

Of the last four earnings reports from Johnson & Johnson, there were 4 positive earnings surprise and 0 negative earnings surprise. The company has EPS estimate of $1.99 for the next earnings report. Johnson & Johnson’s next earnings report date is -.

The consensus rating of Wall Street analysts for Johnson & Johnson is Moderate Buy (1.56), with a target price of $168.25, which is +16.78% compared to the current price. The earnings rating for Johnson & Johnson stock is Neutral (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Johnson & Johnson has a dividend yield of 2.76% with a dividend per share of $4.04 and a payout ratio of 67.00%.

Johnson & Johnson has a Buy technical analysis rating based on Technical Indicators (ADX : 17.67, ATR14 : 3.02, CCI20 : 98.52, Chaikin Money Flow : -0.18, MACD : -0.46, Money Flow Index : 65.21, ROC : 3.25, RSI : 59.64, STOCH (14,3) : 91.00, STOCH RSI : 0.95, UO : 45.86, Williams %R : -9.00), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Johnson & Johnson in the last 12-months were: Alex Gorsky (Option Excercise at a value of $0), Ashley McEvoy (Option Excercise at a value of $0), Ashley McEvoy (Sold 29 000 shares of value $4 276 630 ), Hubert Joly (Buy at a value of $706 399), Jennifer L. Taubert (Option Excercise at a value of $0), Joaquin Duato (Option Excercise at a value of $0), Joseph J. Wolk (Option Excercise at a value of $0), Kathryn E. Wengel (Option Excercise at a value of $1 153 628), Kathryn E. Wengel (Sold 18 132 shares of value $2 758 475 ), Kathy Wengel (Option Excercise at a value of $126 305), Kathy Wengel (Sold 2 017 shares of value $284 538 ), Michael E. Sneed (Option Excercise at a value of $3 639 975), Michael E. Sneed (Sold 58 128 shares of value $8 683 568 ), Michael H. Ullmann (Option Excercise at a value of $0), Michael Sneed (Option Excercise at a value of $3 639 975), Michael Sneed (Sold 58 128 shares of value $8 683 568 ), Paulus Stoffels (Option Excercise at a value of $0), Peter M. Fasolo (Option Excercise at a value of $0), Robert J. Decker (Option Excercise at a value of $0), Thibaut Mongon (Option Excercise at a value of $1 738 618), Thibaut Mongon (Sold 39 224 shares of value $5 803 583 ), William D. Perez (Buy at a value of $63 843)

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
11 (68.75 %)
11 (68.75 %)
10 (66.67 %)
Moderate Buy
1 (6.25 %)
1 (6.25 %)
1 (6.67 %)
Hold
4 (25.00 %)
4 (25.00 %)
4 (26.67 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingModerate Buy
1.56
Moderate Buy
1.56
Moderate Buy
1.60

Johnson & Johnson

Johnson & Johnson is the world's largest and most diverse healthcare company. Three divisions make up the firm: pharmaceutical, medical devices and diagnostics, and consumer. The drug and device groups represent close to 80% of sales and drive the majority of cash flows for the firm. The drug division focuses on the following therapeutic areas: immunology, oncology, neurology, pulmonary, cardiology, and metabolic diseases. The device segment focuses on orthopedics, surgery tools, vision care, and a few smaller areas. The last segment of consumer focuses on baby care, beauty, oral care, over-the-counter drugs, and women's health. Geographically, close to half of total revenue is generated in the United States.

CEO: Alex Gorsky

Teplephone: +1 732 524-0400

Address: One Johnson & Johnson Plaza, New Brunswick 08933, NJ, USA

Number of employees: 135 100

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

0%100%

Bearish Bullish

59%41%

Bearish Bullish

54%46%

Bearish Bullish

50%50%

News

Stocktwits